Xtandi becomes first FDA approved oral treatment for prostate cancer

Prostate cancer is the second most common cancer among men worldwideMetastatic allyted prostate cancer means that the cancer of patients has spread from the prostate to other parts of the body, but these patients' tumors can still respond to treatments that lower androgen levelsAccording to statistics, in the United States, about 40,000 people will have mHSPC in 2019Xtandi is a specific androgen receptor inhibitor that not only blocks androgen stake-receptor binding, but also inhibits receptor-to-intracellular transfer, as well as androgen receptor-DNA bindingSo it's not just an antagonists for androgen receptors, it also inhibits androgen signaling pathwaysPhase 3 clinical trial, known as ARCHES, showed that Xtandi and ADT combined reduced the risk of radiology progression or death in patients by 61% compared to placebo and androgen deprivation therapy (ADT) (HR-0.39, 95% CI: 0.30-0.50, p 0.0001)At the same time, prostate-specific antigens (PSAs) in more patients in the Xtandi-ADT treatment group were reduced to undetectable levels (p 0.001)The results of this trial have been published in Journal of Oncolog Clinicaly,", "Since it was first approved in 2012, Xtandi has become the standard treatment for patients with aggressive prostate cancer worldwide, treating more than 420,000 patients worldwide," said DrAndrew Krivoshik, senior vice president and head of oncology therapy at AstellasReferences:xtANDI ® (enzalutamide) Approved by U.SFDA for the Treatment of Metastatic Caststatic-Sensitive Prostate CancerOrigind December 16, 2019, from https://original title: Courier - For more prostate cancer patients, FDA approves Pfizer/Astellas oral therapy extended indications